Price T Rowe Associates Inc Cullinan Oncology, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 29,493 shares of CGEM stock, worth $281,068. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,493
Previous 25,569
15.35%
Holding current value
$281,068
Previous $429,000
16.08%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding CGEM
# of Institutions
153Shares Held
68.3MCall Options Held
549KPut Options Held
118K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$72.9 Million13.93% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$54.8 Million2.62% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$33.8 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$32.5 Million15.23% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.38MShares$32.2 Million1.02% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $435M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...